Published in Clin Infect Dis on January 01, 2010
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev (2014) 2.26
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother (2011) 1.41
Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases. Clin Microbiol Infect (2011) 1.39
Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country. PLoS One (2013) 1.29
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2010) 1.29
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother (2011) 1.29
Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol (2011) 1.14
Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol (2010) 1.12
Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis (2012) 1.11
Dominance of CTX-M-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS One (2014) 1.11
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center. Antimicrob Agents Chemother (2013) 1.07
Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study. PLoS One (2012) 1.07
Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli over a 6-year period. J Korean Med Sci (2013) 1.07
Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15. BMC Infect Dis (2012) 1.06
In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario? Antimicrob Agents Chemother (2011) 1.04
Predictors of hospital surface contamination with Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: patient and organism factors. Antimicrob Resist Infect Control (2014) 1.01
Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev (2013) 1.01
Foodborne urinary tract infections: a new paradigm for antimicrobial-resistant foodborne illness. Front Microbiol (2013) 0.98
Virulence profiles of bacteremic extended-spectrum β-lactamase-producing Escherichia coli: association with epidemiological and clinical features. PLoS One (2012) 0.97
Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study. Interdiscip Perspect Infect Dis (2012) 0.93
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis (2013) 0.88
Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest (2015) 0.87
Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems. Antimicrob Agents Chemother (2011) 0.87
Molecular characterization of multiresistant Escherichia coli producing or not extended-spectrum β-lactamases. BMC Microbiol (2013) 0.87
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother (2015) 0.86
Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli. Antimicrob Agents Chemother (2012) 0.85
Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital. Korean J Intern Med (2014) 0.85
Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series. BMC Infect Dis (2014) 0.84
Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore) (2014) 0.84
Extended-spectrum β-lactamase-producing enterobacteriaceae in community-acquired urinary tract infections in São Luís, Brazil. Braz J Microbiol (2013) 0.83
Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control study. BMC Infect Dis (2014) 0.83
[Community-acquired pneumonia: a disease of the elderly]. Z Gerontol Geriatr (2011) 0.81
Risk factors for extended-spectrum beta-lactamase-producing Escherichia coli infection in hospitalized patients. Nagoya J Med Sci (2012) 0.81
Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems. Eur J Clin Microbiol Infect Dis (2017) 0.80
Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: a multicentre case-case comparison study. Antimicrob Resist Infect Control (2014) 0.80
Risk Factors for and Outcomes of Bacteremia Caused by Extended-Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiella Species at a Canadian Tertiary Care Hospital. Can J Hosp Pharm (2015) 0.80
Extended-spectrum beta-lactamase-positive Escherichia coli causing complicated upper urinary tract infection: Urologist should act in time. Urol Ann (2014) 0.80
Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome. Eur J Clin Microbiol Infect Dis (2014) 0.79
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. PLoS One (2013) 0.79
Comparative epidemiology of CTX-M-14 and CTX-M-15 producing Escherichia coli: association with distinct demographic groups in the community in New Zealand. Eur J Clin Microbiol Infect Dis (2012) 0.79
Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France. Medicine (Baltimore) (2016) 0.78
Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards. Biomed Res Int (2015) 0.78
Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia. Yonsei Med J (2014) 0.78
Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study. BMC Infect Dis (2013) 0.78
The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care (2011) 0.77
Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients. Antimicrob Agents Chemother (2016) 0.77
Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia. Eur J Clin Microbiol Infect Dis (2011) 0.77
In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia. Antimicrob Agents Chemother (2015) 0.75
A simple scoring algorithm predicting extended-spectrum β-lactamase producers in adults with community-onset monomicrobial Enterobacteriaceae bacteremia: Matters of frequent emergency department users. Medicine (Baltimore) (2017) 0.75
Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections. Korean J Intern Med (2016) 0.75
Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Infect Dis (2010) 0.75
Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli. Korean J Intern Med (2015) 0.75
Multiresistant bacterial infections in liver cirrhosis: Clinical impact and new empirical antibiotic treatment policies. World J Hepatol (2015) 0.75
Think (Gram) negative! Crit Care (2010) 0.75
Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital. Intern Med (2017) 0.75
Antimicrobial Susceptibilities of Enterobacteriaceae in Community-Acquired Urinary Tract Infections during a 5-year Period: A Single Hospital Study in Korea. Infect Chemother (2017) 0.75
Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis (2013) 4.27
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis (2006) 3.79
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis (2011) 3.40
Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother (2002) 3.23
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med (2008) 3.23
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol (2004) 3.20
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother (2003) 3.13
A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med (2006) 3.12
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis (2013) 3.06
Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA (2007) 3.03
Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med (2014) 2.95
Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J (2004) 2.85
qnr Gene nomenclature. Antimicrob Agents Chemother (2008) 2.81
A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis (2012) 2.46
Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis (2008) 2.27
Coevolution with viruses drives the evolution of bacterial mutation rates. Nature (2007) 2.23
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A (2014) 2.20
Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog (2009) 2.20
A randomized trial of intravenous glutamine supplementation in trauma ICU patients. Intensive Care Med (2014) 2.19
Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother (2003) 2.19
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother (2010) 2.16
Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother (2006) 2.16
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis (2003) 2.13
Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods (2008) 2.10
[Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia]. Enferm Infecc Microbiol Clin (2006) 2.09
Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother (2005) 2.08
Epidemiology of extended-spectrum beta-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol (2002) 2.04
Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2005) 1.97
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother (2004) 1.88
Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother (2010) 1.81
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc) (2005) 1.78
Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents (2009) 1.74
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis (2014) 1.73
Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol (2006) 1.73
Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis (2004) 1.71
Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med (2007) 1.69
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect (2009) 1.68
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr (2008) 1.68
High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol (2008) 1.64
[Acinetobacter baumannii bacteremia: clinical and prognostic features]. Enferm Infecc Microbiol Clin (2003) 1.61
Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther (2008) 1.60
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials (2012) 1.59
Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis (2004) 1.58
Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother (2012) 1.56
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2009) 1.55
Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. AIDS (2012) 1.55
Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis (2008) 1.54
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother (2011) 1.54
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother (2003) 1.54
Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.53
[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)]. Enferm Infecc Microbiol Clin (2003) 1.53
Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis (2005) 1.52
Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis (2013) 1.52
Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother (2008) 1.51
Metallo-beta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J Antimicrob Chemother (2010) 1.50
[Tuberculous meningitis: a comparative study in relation to concurrent human immunodeficiency virus infection]. Enferm Infecc Microbiol Clin (2006) 1.50
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
Plasmid-mediated quinolone resistance: an update. J Infect Chemother (2010) 1.48
[Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update]. Enferm Infecc Microbiol Clin (2011) 1.46
Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol (2004) 1.46
Functional characterization of twelve natural PROS1 mutations associated with anticoagulant protein S deficiency. Haematologica (2008) 1.45
[Molecular characterization of a glycopeptide-resistant Enterococcus faecalis outbreak in an intensive care unit]. Enferm Infecc Microbiol Clin (2005) 1.44
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob Agents Chemother (2009) 1.44
[Characterization and molecular epidemiology of ESBL in Escherichia coli and Klebsiella pneumoniae in 11 Spanish hospitals (2004)]. Enferm Infecc Microbiol Clin (2008) 1.43
Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. Enferm Infecc Microbiol Clin (2011) 1.43
Internal and external validation of a model to predict adverse outcomes in patients with left-sided infective endocarditis. Heart (2011) 1.43
[Activity and penetration of linezolid and vancomycin against Staphylococcus epidermidis biofilms]. Enferm Infecc Microbiol Clin (2007) 1.43
[Predictive factors for pneumonia in adults infected with the new pandemic A (H1H1) influenza virus]. Rev Esp Quimioter (2011) 1.42
Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.42
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin (2004) 1.41
Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation (2013) 1.40
Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2003) 1.40
[Infective endocarditis in the XXI century: epidemiological, therapeutic, and prognosis changes]. Enferm Infecc Microbiol Clin (2012) 1.40
[Meningitis outbreak caused by Echovirus serotype 30 in the Valencian Community]. Enferm Infecc Microbiol Clin (2009) 1.39
[Comparison of 3 methods for determining sensitivity to imipenem and meropenem in Acinetobacter baumannii with a carbapenem-heteroresistant phenotype]. Enferm Infecc Microbiol Clin (2008) 1.39
[Control of methicillin-resistant Staphylococcus aureus in Spanish hospitals. A survey from the MRSA 2003 GEIH/GEMARA/REIPI project]. Enferm Infecc Microbiol Clin (2006) 1.39
[Patient characteristics and health care burden during the influenza A (H1N1) 2009 pandemic in the university Hospital Vall d'Hebron of Barcelona]. Enferm Infecc Microbiol Clin (2011) 1.38
National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother (2011) 1.38
Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother (2002) 1.37
PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol Microbiol (2006) 1.35
Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J Clin Microbiol (2011) 1.35
Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. Am J Med (2005) 1.34
Multiplex PCR of sonication fluid accurately differentiates between prosthetic joint infection and aseptic failure. J Infect (2012) 1.33
Acute viral gastroenteritis: proportion and clinical relevance of multiple infections in Spanish children. J Med Microbiol (2003) 1.30